VIM and thyroid cancer: As can be seen from the results of Figure 6G, compared to single-agent treatment, the combination of lenvatinib with either KPT-330 or KPT-9274 caused greater inhibition of EMT marker Vimentin. These results support the use of KPT-330 or KPT-9274 either as single agents or in combination with lenvatinib for therapy resistant thyroid cancer.